On 23 September 2026, HENLIUS (02696.HK) said it signed a collaboration and licence deal with Amberstone for two T cell engager products on the T-MATE platform.
Hong Kong stocks fell on September 23, with the HSI down 1.01%. PONY-W gained 5.07% while Z.AI plunged 12.40% as AI concept stocks pulled back broadly.
On 23 September 2026, BIDU-W (09888.HK) traded weaker. As of 15:14, it was quoted at HK$88.85, down 0.73%.
HUA HONG GRACE (01347.HK) rose 0.26% to HKD 114.100. UMC flagged fresh mature-node price hikes and PSMC a 40% rise; T-Head launched the Zhenwu V900 AI chip.
EXCELLAND ROBOT (03231.HK) rose 0.77% to HKD 39.300. HONY MEDIA tied up with Excelland Technology and four robotics firms; Scalabot released a spatial model.
On 23 September 2026, GENFLEET-B (02595.HK) said its GFH276 monotherapy data were selected as an ESMO LBA; investor calls are set for 15 and 25 October.
On 22 September 2026, CIRC (01763.HK) said its subsidiary CNGT's Lu-177 API DMF passed U.S. FDA review, with the DMF number activated for downstream citation.
On September 22, 2026, RoboSense (02498.HK) edged slightly lower in the afternoon. At market close, it was quoted at HK$16.91, down 0.06%.
Hong Kong stocks closed slightly higher on September 22, with the HSI up 0.18%. MONTAGETECH led AI concept stocks with an 8.10% gain, while Z.AI fell 6.55%.
ASMPT (00522.HK) rose 2.03% to HKD 170.800. Intel and AUO are developing Micro LED substrate packaging; Samsung plans to double HBM4-series output.
XIAOMI-W (01810.HK) rose 0.29% to HKD 27.660. Unitree launched the 22-DoF Dex5-S dexterous hand; GENISOM AI completed a B round.
On 22 September 2026, GENFLEET-B (02595.HK) announced that its clinical program of GFH375 combined with cetuximab was placed on the proposed BTD list on 18 September 2026 for KRAS G12D mutant metastatic colorectal cancer.
On 21 September 2026, HENGRUI PHARMA (01276.HK) announced NMPA approval for clinical trials of HRS-4729 injection in chronic kidney disease and HRS-1596 tablets for weight management and type 2 diabetes, with cumulative R&D investment of about RMB 106 million.
On 21 September 2026, CF PHARMTECH (02652.HK) announced that its Phase I clinical trial of ICF004, an inhalation powder for interstitial lung disease, has completed enrolment and dosing of its first healthy subject, with further studies planned.
On 21 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary received NMPA approval for clinical trials of SHR-4595 for injection in patients with advanced solid tumours, with cumulative R&D investment of about RMB 16.4 million.
On 21 September 2026, LEADS BIOLABS-B (09887.HK) said its pivotal LBL-024 EP-NEC trial was selected as an ESMO 2026 late-breaking abstract.
